Condition
Cerebral Cavernous Malformations
Total Trials
4
Recruiting
0
Active
0
Completed
1
Success Rate
33.3%-53% vs avg
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
50.0%
2 terminated out of 4 trials
Success Rate
33.3%
-53.2% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
33% success
Data Visualizations
Phase Distribution
2Total
Early P 1 (1)
P 2 (1)
Trial Status
Terminated2
Unknown1
Completed1
Trial Success Rate
33.3%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT01764529Completed
Modifiers of Disease Severity in Cerebral Cavernous Malformations
NCT03474614Phase 2TerminatedPrimary
Effect of Oral Propranolol on mRNA Expresssion in Symptomatic Cavernous Malformation
NCT01764451Early Phase 1Terminated
Permeability MRI in Cerebral Cavernous Malformations Type 1 in New Mexico: Effects of Statins
NCT03467295UnknownPrimary
Treatments and Outcomes of Untreated Cerebral Cavernous Malformations in CHina.
Showing all 4 trials